Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.

Luis de la Cruz-Merino,Alejandro Martín,Esteban Nogales Fernández,Fernando Carnicero González,Eduardo Rios-Herranz,Fátima de la Cruz-Vicente,Guillermo Rodriguez,Concepción Nicolás,Natividad Martinez-Banaclocha,Josep Gumà,José Gómez-Codina,Antonio Salar Silvestre,Delvys Rodriguez Abreu,Christina Quero Blanco,Jorge Labrador Gómez,M. Guirado,Natalia Palazón-Carrión,Pablo Espejo García,Mariano Provencio-Pulla,Antonio Rueda Domínguez

Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.

2020

8019Background: Lenalidomide is an immunomodulatory drug that could reverse rituximab refractoriness in lymphoma patients (pts). We conducted an open label multicenter phase 2 trial testing the eff...

Keywords:

Oncology
Lenalidomide
Diffuse large B-cell lymphoma
Internal medicine
Pathology
relapsed refractory
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations